Literature DB >> 21152153

Atypical presentations of atypical antipsychotics.

Cpt Christopher K Lind, Cpt Lisa R Carchedi, Ltc James J Staudenmeier, Ltc P Carroll J Diebold.   

Abstract

The atypical antipsychotics have been touted by many as having minimal extrapyramidal symptoms. This case series from the Tripler Army Medical Center Psychiatry Graduate Medical Education Program presents the extrapyramidal symptoms observed with four different atypical antipsychotic medications. Also reviewed are the mechanisms of action that atypical antipsychotics and first-generation antipsychotics use to treat the symptoms of schizophrenia. Cases reviewed include a schizophrenic male patient whose dose of risperidone was doubled from 6mg to 12mg overnight and developed an acute dystonic reaction; a young male patient with a substance-induced psychosis who unintentionally doubled his ziprasidone dose in 24 hours, resulting in an acute dystonic reaction; a young female patient on paroxetine who also recently started olanzapine and had complaints consistent with akathisia that resolved with treatment; and an adolescent female patient on escitalopram for obsessive-compulsive disorder who after starting aripiprazole developed Parkinsonism. All four cases illustrate that even though atypical antipsychotics are less likely to cause extrapyramidal symptoms than their first generation cousins, the physician should be aware that these symptoms may still occur and need to be treated.

Entities:  

Year:  2005        PMID: 21152153      PMCID: PMC3000190     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  8 in total

1.  Aripiprazole and extrapyramidal symptoms.

Authors:  Rahsaan L Lindsey; Desmond Kaplan; Vassilis Koliatsos; J Ken Walters; Neil B Sandson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-11       Impact factor: 8.829

Review 2.  SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.

Authors:  R M Lane
Journal:  J Psychopharmacol       Date:  1998       Impact factor: 4.153

3.  Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone.

Authors:  P I Rosebush; M F Mazurek
Journal:  Neurology       Date:  1999-03-10       Impact factor: 9.910

4.  Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.

Authors:  J Peuskens
Journal:  Br J Psychiatry       Date:  1995-06       Impact factor: 9.319

5.  Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

Authors:  John M Kane; William H Carson; Anutosh R Saha; Robert D McQuade; Gary G Ingenito; Dan L Zimbroff; Mirza W Ali
Journal:  J Clin Psychiatry       Date:  2002-09       Impact factor: 4.384

6.  A prospective, open-label trial of olanzapine in adolescents with schizophrenia.

Authors:  Robert L Findling; Nora K McNamara; Eric A Youngstrom; Lisa A Branicky; Christine A Demeter; S Charles Schulz
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2003-02       Impact factor: 8.829

Review 7.  Evidence-based treatment for schizophrenia.

Authors:  Anthony F Lehman; Robert W Buchanan; Faith B Dickerson; Lisa B Dixon; Richard Goldberg; Lisa Green-Paden; Julie Kreyenbuhl
Journal:  Psychiatr Clin North Am       Date:  2003-12

8.  Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.

Authors:  Kevin D Burris; Thaddeus F Molski; Cen Xu; Elaine Ryan; Katsura Tottori; Tetsuro Kikuchi; Frank D Yocca; Perry B Molinoff
Journal:  J Pharmacol Exp Ther       Date:  2002-07       Impact factor: 4.030

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.